BR112022021563A2 - Receptores de antígeno quimérico que alvejam cd19 e uso dos mesmos - Google Patents

Receptores de antígeno quimérico que alvejam cd19 e uso dos mesmos

Info

Publication number
BR112022021563A2
BR112022021563A2 BR112022021563A BR112022021563A BR112022021563A2 BR 112022021563 A2 BR112022021563 A2 BR 112022021563A2 BR 112022021563 A BR112022021563 A BR 112022021563A BR 112022021563 A BR112022021563 A BR 112022021563A BR 112022021563 A2 BR112022021563 A2 BR 112022021563A2
Authority
BR
Brazil
Prior art keywords
chimeric antigen
antigen receptors
cars
target
receptors targeting
Prior art date
Application number
BR112022021563A
Other languages
English (en)
Inventor
Feucht Judith
MANSILLA-SOTO Jorge
Riviere Isabelle
Sadelain Michel
Vincent Loic
Shapiro Gary
Rosa Ng Mei
Tavares Dan
He Xingyue
Original Assignee
Memorial Sloan Kettering Cancer Center
Millennium Pharm Inc
Sloan Kettering Inst Cancer Res
Memorial Hospital For Cancer And Allied Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Millennium Pharm Inc, Sloan Kettering Inst Cancer Res, Memorial Hospital For Cancer And Allied Diseases filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112022021563A2 publication Critical patent/BR112022021563A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

RECEPTORES DE ANTÍGENO QUIMÉRICO QUE ALVEJAM CD19 E USO DOS MESMOS. A matéria presentemente revelada fornece receptores de antígeno quimérico (CARs) que alvejam especificamente CD19 e células que compreendem tais CARs que têm como alvo CD19. A matéria presentemente revelada fornece adicionalmente usos dos CARs que têm como alvo CD19 para tratamento, por exemplo, para tratamento de câncer de sangue.
BR112022021563A 2020-04-24 2021-04-26 Receptores de antígeno quimérico que alvejam cd19 e uso dos mesmos BR112022021563A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015362P 2020-04-24 2020-04-24
US202063073133P 2020-09-01 2020-09-01
PCT/US2021/029138 WO2021217130A2 (en) 2020-04-24 2021-04-26 Chimeric antigen receptors targeting cd19 and use thereof

Publications (1)

Publication Number Publication Date
BR112022021563A2 true BR112022021563A2 (pt) 2022-12-27

Family

ID=78270076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021563A BR112022021563A2 (pt) 2020-04-24 2021-04-26 Receptores de antígeno quimérico que alvejam cd19 e uso dos mesmos

Country Status (12)

Country Link
US (1) US20230346938A1 (pt)
EP (1) EP4138865A2 (pt)
JP (1) JP2023515707A (pt)
KR (1) KR20230008144A (pt)
CN (1) CN115916224A (pt)
AU (1) AU2021261429A1 (pt)
BR (1) BR112022021563A2 (pt)
CA (1) CA3183596A1 (pt)
CO (1) CO2022016866A2 (pt)
IL (1) IL297553A (pt)
MX (1) MX2022013393A (pt)
WO (1) WO2021217130A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022021450A2 (pt) * 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
CN117402261A (zh) * 2023-10-17 2024-01-16 北京景达生物科技有限公司 一种基于重组腺病毒的car-nk细胞制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
SG10201913303XA (en) * 2015-07-13 2020-03-30 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
GB201610515D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Cell

Also Published As

Publication number Publication date
CO2022016866A2 (es) 2023-02-16
WO2021217130A3 (en) 2021-12-02
AU2021261429A1 (en) 2022-12-01
JP2023515707A (ja) 2023-04-13
MX2022013393A (es) 2023-02-14
WO2021217130A2 (en) 2021-10-28
CA3183596A1 (en) 2021-10-28
CN115916224A (zh) 2023-04-04
US20230346938A1 (en) 2023-11-02
KR20230008144A (ko) 2023-01-13
IL297553A (en) 2022-12-01
EP4138865A2 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
CO2020000438A2 (es) Anticuerpos anti-ctla-4 y sus usos
CO2018003738A2 (es) Anticuerpos anti-lag3 y sus usos
BR112022021563A2 (pt) Receptores de antígeno quimérico que alvejam cd19 e uso dos mesmos
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
BR112021022504A2 (pt) Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos
CL2021000873A1 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
BR112021022576A2 (pt) Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
UY31478A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112015000776A2 (pt) Agentes de ligação à rspo3 e usos dos mesmos
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
BR112021018456A2 (pt) Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112019009656A2 (pt) copolímeros diblocos automontados compostos por pegmema e segmentos poliméricos contendo fármacos
CL2019000846A1 (es) Proteína terapéutica.
BR112022005423A2 (pt) Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap)
CL2022000030A1 (es) Moléculas de unión a claudina-6 y usos de las mismas
CL2023000630A1 (es) Anticuerpos anti-ceacam5 y sus conjugados y usos.
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al